Avista Healthcare Partners has sold Solmetex, a provider of dental products and systems, to AGIC Capital. Avista is maintaining a minority equity investment in Solmetex in partnership with AGIC Capital.
Solmetex manufactures amalgam separators and other waste compliance products that remove mercury from dental wastewater created by the removal of amalgam fillings. Amalgam fillings contain a mixture of metals, consisting of liquid mercury and a powdered alloy composed of silver, tin, and copper. Approximately half of a dental amalgam is mercury by weight.
Prior to 2017, dental offices typically disposed of amalgam waste down the drain, with the wastewater then processed by sewage treatment plants, which in many cases were not designed to treat or recycle mercury or other heavy metals. Dental amalgam is the largest source of mercury received by U.S. treatment plants. In 2017, the Environmental Protection Agency (EPA) implemented regulations requiring dental practices to incorporate amalgam separators in their drainage systems.
In addition to its amalgam separators, Solmetex provides its dental customers with Sterisil water purification products for dental unit waterlines, DryShield for hands-free dental isolation, Impladent regenerative biomaterials for oral surgery and implant procedures, as well as recycling, disposal, and compliance certification services.
Avista acquired Solmetex in January 2021, and during its ownership completed three add-on acquisitions: Sterisil in April 2022, DryShield in April 2022, and Impladent in June 2023.
Solmetex, led by CEO Gene Dorff, was founded in 1994 and is headquartered 37 miles west of Boston in Northborough, Massachusetts.
“We have greatly valued our partnership with the Solmetex management team, supporting their significant growth over the past four years,” said Sriram Venkataraman, a partner at Avista. “Solmetex’s impressive trajectory has been further bolstered by three strategic acquisitions during our partnership, including Sterisil, DryShield, and Impladent.”
Avista Healthcare Partners makes control or influential minority investments in growth-oriented healthcare businesses, with specific interests in outsourced pharma and medtech services, consumer healthcare, medical devices, specialty and generic pharmaceuticals, distribution and diagnostics, and healthcare technology. The firm was founded in 2005 and is headquartered in New York City.
AGIC Capital is an investor in mid-sized companies with established revenue streams and EBITDA growth potential, particularly in automation, medical technologies, and advanced manufacturing. The firm was founded in 2015 and is headquartered in Hong Kong, with additional offices in Munich, Germany. AGIC Capital closed its most recent fund, AGIC Fund II, in 2021 with $1.2 billion in committed capital.
© 2025 Private Equity Professional | March 20, 2025